SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video describing the program's early activity.
According to the video, Kings Hospital has completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system. This milestone marks a significant advancement for Sri Lanka's healthcare sector, potentially improving patient outcomes and expanding access to minimally invasive cardiac surgery in the region.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures underscore the growing global demand for robotic-assisted surgery and the company's expanding footprint in international markets.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow the company to enter two of the largest medical device markets, potentially accelerating revenue growth and broadening its competitive position against established players in the surgical robotics industry.
For readers in Long Beach and the surrounding area, this news highlights the continued innovation in surgical robotics driven by companies with global reach. While SS Innovations is not headquartered locally, its advancements contribute to the broader medical technology ecosystem that includes research institutions, hospitals, and suppliers in Southern California. The company's progress could also influence local investment trends in healthcare technology and inspire partnerships with regional medical centers.
The successful launch in Sri Lanka, combined with strong procedure growth and upcoming regulatory filings, positions SS Innovations as a notable player in the robotic surgery market. As the company expands its international presence, it may create new opportunities for collaboration and adoption of robotic systems in other underserved regions. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, please visit https://IBN.ai/Disclaimer.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
